Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology
Disease Category: Neuropathy
Trial Information
Have you been diagnosed with Multifocal Motor Neuropathy?
According to the National Institute of Neurological Disorders and Stroke, Multifocal Motor Neuropathy (MMN) is a progressive muscle disorder characterized by muscle weakness in the arms or legs, with one side affected more than the other. The disease is thought to have an immune component and is often treated with immune-modifying therapies. This randomized, double-blind (DB), placebo-controlled, cross-over, multicenter study is being done to examine the effectiveness of intravenous immunoglobulin (IVIG or IGIV) for the treatment of MMN.
Patient Inclusion Criteria:
- Must be at least 18 years old
- Diagnosis of definite or probably MMN
- Must be on a stable regimen of IGIV for at least 3 months, with a treatment interval of 2 to 5 weeks
Patient Exclusion Criteria:
- Treatment with other immunosuppressive agents besides IGIV within 3 months of enrollment or with Rituximab in the past 12 months prior to enrollment
- Any clinical or electrophysiological evidence of coexisting neuropathy which may interfere with outcome assessments
- Current participation or participation in the last 30 days in an investigational drug trial
Lauren Friedman, Clinical Research Coordinator
1st International Clinical Research Center
7286 S. Yosemite St. Ste 180
Centennial, CO 80112
Phone: 303-224-4700
EMail: lfriedman@immunoe.com
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
